ArticleFrontiers in neurology2025
Modulation of brain activity and tremor severity by NeuroEpo in Parkinson's patients with varying tremor amplitudes.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tremors, particularly those related to Parkinson's disease (PD), significantly affect quality of life. In this study, we inspected the effects of NeuroEpo versus placebo on brain function and tremor inhibition in patients with high-amplitude tremors (HAT) and low-amplitude tremors (LAT). Objectives: To assess the efficacy of NeuroEpo in enhancing coherence and power spectral density (PSD) relative to tremor severity, and to explore differences in stimulation parameters and medication requirements between patients with HAT and LAT. Methods: A double-blind randomized controlled trial was conducted on 16 participants diagnosed with PD. Participants were stratified into the HAT ( Results: NeuroEpo treatment produced a significant increase in coherence and PSD, particularly in the 20-21 Hz frequency band, compared with placebo. Patients with LAT required higher stimulation intensities and medication doses than those with HAT, suggesting a more complex disease profile. The combination of NeuroEpo and DBS resulted in improved both motor and cognitive functions. A two-way ANOVA indicated a significant main effect of treatment ( Conclusion: NeuroEpo may provide an adjuvant therapeutic aid for the control of tremor and improvement in brain function in PD patients. Customized treatment approaches incorporating tremor amplitude may improve therapeutic benefit and patient well-being. Future research should follow up on the long-term psychosocial effects of combined interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.